RNA Interference for Antimetastatic Therapy

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• RNA interference (RNAi) is a promising cancer treatment strategy.
• Effective delivery and sustained presence of interfering molecules are crucial for RNAi therapy.
• Targeting metastasis-driving genes is key to preventing cancer spread.

Purpose of the Study:

• To describe a method for systemic application of shRNA expression plasmid for cancer therapy.
• To evaluate the efficacy of targeting S100A4 in reducing colorectal cancer metastasis.
• To demonstrate sustained reduction of target gene expression in primary tumors.

Main Methods:

• Systemic administration of shRNA expression plasmid via tail vein injection in xenograft mice.
• Selection of S100A4 as a metastasis-driving target gene.
• In vivo imaging to monitor tumor growth and metastasis formation.
• End point analysis including metastatic burden scoring and gene expression quantification.

Main Results:

• Sustained reduction of target gene expression in the primary tumor.
• Restricted formation of distant colorectal cancer metastases.
• Average S100A4 expression reduced by 30% in tumor tissues.
• Significant 70% decrease in liver metastases.

Conclusions:

• Systemic shRNA plasmid delivery is an effective method for cancer therapy.
• Targeting S100A4 with RNAi can significantly inhibit colorectal cancer metastasis.
• This approach offers a potential strategy for controlling metastatic disease.